{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4"},{"groupId":"OG001","value":"66.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2288"},{"groupId":"OG001","value":"2308"}],"units":"Participants"}],"title":"Baseline: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4"},{"groupId":"OG001","value":"32.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2288"},{"groupId":"OG001","value":"2308"}],"units":"Participants"}],"title":"Baseline: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2"},{"groupId":"OG001","value":"1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2288"},{"groupId":"OG001","value":"2308"}],"units":"Participants"}],"title":"Baseline: Unable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8"},{"groupId":"OG001","value":"54.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2078"},{"groupId":"OG001","value":"2128"}],"units":"Participants"}],"title":"Week 13: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.1"},{"groupId":"OG001","value":"43.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2078"},{"groupId":"OG001","value":"2128"}],"units":"Participants"}],"title":"Week 13: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"groupId":"OG001","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2078"},{"groupId":"OG001","value":"2128"}],"units":"Participants"}],"title":"Week 13: Unable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.5"},{"groupId":"OG001","value":"65.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2059"},{"groupId":"OG001","value":"2077"}],"units":"Participants"}],"title":"Week 25: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.2"},{"groupId":"OG001","value":"32.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2059"},{"groupId":"OG001","value":"2077"}],"units":"Participants"}],"title":"Week 25: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2059"},{"groupId":"OG001","value":"2077"}],"units":"Participants"}],"title":"Week 25: Unable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4"},{"groupId":"OG001","value":"72.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2049"},{"groupId":"OG001","value":"2102"}],"units":"Participants"}],"title":"EOT: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3"},{"groupId":"OG001","value":"26.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2049"},{"groupId":"OG001","value":"2102"}],"units":"Participants"}],"title":"EOT: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2049"},{"groupId":"OG001","value":"2102"}],"units":"Participants"}],"title":"EOT: Unable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5"},{"groupId":"OG001","value":"76.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1919"},{"groupId":"OG001","value":"1918"}],"units":"Participants"}],"title":"FU Month 18: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6"},{"groupId":"OG001","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1919"},{"groupId":"OG001","value":"1918"}],"units":"Participants"}],"title":"FU Month 18: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1919"},{"groupId":"OG001","value":"1918"}],"units":"Participants"}],"title":"FU Month 18: Unable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7"},{"groupId":"OG001","value":"79.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1862"},{"groupId":"OG001","value":"1875"}],"units":"Participants"}],"title":"FU Month 24: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4"},{"groupId":"OG001","value":"19.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1862"},{"groupId":"OG001","value":"1875"}],"units":"Participants"}],"title":"FU Month 24: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1862"},{"groupId":"OG001","value":"1875"}],"units":"Participants"}],"title":"FU Month 24: Unable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9"},{"groupId":"OG001","value":"79.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1821"},{"groupId":"OG001","value":"1794"}],"units":"Participants"}],"title":"FU Month 36: No problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3"},{"groupId":"OG001","value":"19.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1821"},{"groupId":"OG001","value":"1794"}],"units":"Participants"}],"title":"FU Month 36: Some problems"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7"},{"groupId":"OG001","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1821"},{"groupId":"OG001","value":"1794"}],"units":"Participants"}],"title":"FU Month 36: Unable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2400"},{"groupId":"OG001","value":"2404"}],"units":"Participants"}],"description":"EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \\[scored as 1\\], some or moderate problems \\[scored as 2\\], and extreme problems \\[scored as 3\\]). Percentage of participants with each of the following responses in usual activities domain was reported: I have no problems with performing my usual activities; I have some problems with performing my usual activities; and I am unable to perform my usual activities. Response percentages may not add up to 100% due to data rounding.","groups":[{"description":"Participants received pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).","id":"OG000","title":"Pertuzumab + Trastuzumab + Chemotherapy"},{"description":"Participants received placebo matched to pertuzumab IV Q3W and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin AUC 6 (up to 900 mg).","id":"OG001","title":"Placebo + Trastuzumab + Chemotherapy"}],"paramType":"NUMBER","populationDescription":"ITT population. Number analyzed=participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36","title":"Percentage of Participants With Response for EQ-5D-3L Questionnaire: Usual Activities Domain","type":"SECONDARY","unitOfMeasure":"percentage of participants"}